Abstract
This article will introduce a novel concept in the use of TGF-β insensitive host immune cells in cancer therapy. TGF-β is a multi-functional cytokine. At a cellular level, it mediates cellular proliferation, growth arrest, differentiation and apoptosis. Because of the above cellular effects, TGF-β is able to regulate a host of patho-physiological events in vivo , such as normal embryonic development, angiogenesis in tumor tissues, malignant transformation and immune surveillance. As a general rule, its direct effect on cancer cells is inhibition to cancer growth. However cancer cells are able to acquire the ability to evade this inhibitory effect of TGF-β by becoming insensitive to TGF-β. Furthermore, these malignant cells are able to produce large quantities of TGF-β. The consequence of over expression of TGF-β by cancer cells is an important factor for subsequent tumor progression. The excess amount of TGF-β promotes tumor angiogenesis and immune suppression. The latter effect of TGF-β is the most devastating to the host. The present discussion is focused on the role of TGF-β insensitive immune cells in cancer growth. The host immune system offers a natural defense program against cancer. But, this natural immune surveillance is rendered ineffective by an overproduction of TGF-β derived from the tumor cells. Rendering the host immune cells insensitive to TGF-β in a gene therapy program offers a hope for us to successfully combat against cancer. Based on the above discussion, it is encouraging that there is a possibility for us to achieve a cure in cancer using TGF-β insensitive immune cells in gene therapy.
Keywords: transforming growth factor-beta, cancer therapy, receptors, insensitive immune cells, serine/threonine kinases, Cycline-dependent kinases (cdks),, myc family members, smads family
Current Drug Targets
Title: From TGF-β to Cancer Therapy
Volume: 4 Issue: 3
Author(s): Xuemei Huang and Chung Lee
Affiliation:
Keywords: transforming growth factor-beta, cancer therapy, receptors, insensitive immune cells, serine/threonine kinases, Cycline-dependent kinases (cdks),, myc family members, smads family
Abstract: This article will introduce a novel concept in the use of TGF-β insensitive host immune cells in cancer therapy. TGF-β is a multi-functional cytokine. At a cellular level, it mediates cellular proliferation, growth arrest, differentiation and apoptosis. Because of the above cellular effects, TGF-β is able to regulate a host of patho-physiological events in vivo , such as normal embryonic development, angiogenesis in tumor tissues, malignant transformation and immune surveillance. As a general rule, its direct effect on cancer cells is inhibition to cancer growth. However cancer cells are able to acquire the ability to evade this inhibitory effect of TGF-β by becoming insensitive to TGF-β. Furthermore, these malignant cells are able to produce large quantities of TGF-β. The consequence of over expression of TGF-β by cancer cells is an important factor for subsequent tumor progression. The excess amount of TGF-β promotes tumor angiogenesis and immune suppression. The latter effect of TGF-β is the most devastating to the host. The present discussion is focused on the role of TGF-β insensitive immune cells in cancer growth. The host immune system offers a natural defense program against cancer. But, this natural immune surveillance is rendered ineffective by an overproduction of TGF-β derived from the tumor cells. Rendering the host immune cells insensitive to TGF-β in a gene therapy program offers a hope for us to successfully combat against cancer. Based on the above discussion, it is encouraging that there is a possibility for us to achieve a cure in cancer using TGF-β insensitive immune cells in gene therapy.
Export Options
About this article
Cite this article as:
Huang Xuemei and Lee Chung, From TGF-β to Cancer Therapy, Current Drug Targets 2003; 4 (3) . https://dx.doi.org/10.2174/1389450033491181
DOI https://dx.doi.org/10.2174/1389450033491181 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
Drug-Targeted Approach with Polymer Nanocomposites for Improved Therapeutics
Polymer nanocomposites have been recognized as an advanced and cutting-edge technique in drug targeting administration. These materials combine the unique features of nanoparticles with the adaptability of polymers to produce highly personalized drug administration devices. Integrating nanoparticles containing pharmaceuticals into a polymer matrix enables researchers to regulate the rates at ...read more
RNA Molecules in the Treatment of Human Diseases
Messenger and non-coding RNAs, including long and small transcripts, are mediators of gene expression. Gene expression at the RNA level shows significant aberrations in human diseases, including cancer, leukemia, lymphoma, cardiovascular diseases, and neurological disorders. Human transcripts serve either as biomarkers of diagnosis, prognosis, prediction of treatment response and/or therapy ...read more
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Targeting the Folate Receptor: Effects of Conjugating Folic Acid to DOX Loaded Polymeric Micelles
Anti-Cancer Agents in Medicinal Chemistry Curcumin: Structure-Activity Relationship Towards its Role as a Versatile Multi-Targeted Therapeutics
Mini-Reviews in Organic Chemistry Aloperine Induces Apoptosis by a Reactive Oxygen Species Activation Mechanism in Human Ovarian Cancer Cells
Protein & Peptide Letters Nitric Oxide Releasing Nanomaterials for Cancer Treatment: Current Status and Perspectives
Current Topics in Medicinal Chemistry Recent Patents on Thiazole Derivatives Endowed with Antitumor Activity
Recent Patents on Anti-Cancer Drug Discovery Advanced Approaches of Bioactive Peptide Molecules and Protein Drug Delivery Systems
Current Pharmaceutical Design Molecular Targets from VHL Studies into the Oxygen-Sensing Pathway
Current Cancer Drug Targets Chemodiversity in Freshwater and Terrestrial Cyanobacteria – A Source for Drug Discovery
Current Drug Targets The Role of PEDF in Tumor Growth and Metastasis
Current Molecular Medicine Clients and Oncogenic Roles of Molecular Chaperone gp96/grp94
Current Topics in Medicinal Chemistry An Overview of Targeting Legumain for Inhibiting Cancers
Current Pharmaceutical Design Control of Neuropathic Pain by Immune Cells and Opioids
CNS & Neurological Disorders - Drug Targets The Emerging Role of Sunitinib in the Treatment of Advanced Epithelial Thyroid Cancer: Our Experience and Review of Literature
Mini-Reviews in Medicinal Chemistry DLEU1: A Functional Long Noncoding RNA in Tumorigenesis
Current Pharmaceutical Design Bioactivity of Chitosan and Its Derivatives
Current Organic Chemistry Drug Metabolism and Individualized Medicine
Current Drug Metabolism Resistance to Radiotherapy and Targeted Molecular Therapies in Squamous Cell Carcinomas of the Head and Neck, Preclinical Data and New Approaches
Current Signal Transduction Therapy Radiation and Gene Therapy: Rays of Hope for the New Millennium?
Current Gene Therapy Molecular Targets, Anti-cancer Properties and Potency of Synthetic Indole-3-carbinol Derivatives
Mini-Reviews in Medicinal Chemistry CDK Inhibitors Induce Mitochondria-mediated Apoptosis Through the Activation of Polyamine Catabolic Pathway in LNCaP, DU145 and PC3 Prostate Cancer Cells
Current Pharmaceutical Design